| Code | CSB-RA015007MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to GCK-01, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a B-cell specific surface antigen expressed during most stages of B-cell development, from pre-B cells to mature B lymphocytes, but absent on plasma cells. This transmembrane protein plays a crucial role in regulating B-cell activation, proliferation, and calcium influx across the cell membrane. MS4A1 is critically implicated in various B-cell malignancies including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and B-cell acute lymphoblastic leukemia, as well as autoimmune disorders such as rheumatoid arthritis and multiple sclerosis.
GCK-01 represents a therapeutic antibody designed to selectively target CD20-positive B cells, inducing cell depletion through multiple mechanisms including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This biosimilar antibody provides researchers with a valuable tool for investigating B-cell biology, exploring mechanisms of B-cell depletion, studying immune-mediated diseases, and evaluating potential therapeutic strategies in oncology and autoimmune research settings.
There are currently no reviews for this product.